Prediabetes and Risk for Cardiac Death Among Patients With Coronary Artery Disease: The ARTEMIS Study
| العنوان: | Prediabetes and Risk for Cardiac Death Among Patients With Coronary Artery Disease: The ARTEMIS Study |
|---|---|
| المؤلفون: | M. Juhani Junttila, Robert J. Myerburg, Olli Pekka Piira, Antti M. Kiviniemi, Olavi Ukkola, Juha S. Perkiömäki, Mikko P. Tulppo, Heikki V. Huikuri, E. Samuli Lepojärvi, Tuomas Kenttä |
| المصدر: | Diabetes Care. 42:1319-1325 |
| بيانات النشر: | American Diabetes Association, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Advanced and Specialized Nursing, medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, medicine.disease, Impaired fasting glucose, Coronary artery disease, Impaired glucose tolerance, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Cardiology, 030212 general & internal medicine, Prediabetes, business, Mace, Glycemic |
| الوصف: | OBJECTIVE To compare cardiac mortality in patients with CAD and prediabetes with that in CAD patients with normal glycemic status and type 2 diabetes. RESEARCH DESIGN AND METHODS The Innovation to Reduce Cardiovascular Complications of Diabetes at the Intersection (ARTEMIS) study included patients with CAD after revascularization (79%), optimal medical therapy, or both. Patients had type 2 diabetes (n = 834), impaired glucose tolerance (IGT; n = 314), impaired fasting glucose (IFG; n = 103), or normal glycemic status (n = 697) as defined on the basis of the results of an oral glucose tolerance test. The primary end point was cardiac death. Major adverse cardiac event (MACE: cardiac death, heart failure, or acute coronary syndrome) and all-cause mortality were secondary end points. RESULTS During a mean ± SD follow-up of 6.3 ± 1.6 years, 101 cardiac deaths, 385 MACEs, and 208 deaths occurred. Patients with IGT tended to have 49% lower adjusted risk for cardiac death (P = 0.069), 32% lower adjusted risk for all-cause mortality (P = 0.076), and 36% lower adjusted risk for MACE (P = 0.011) than patients with type 2 diabetes. The patients with IFG had 82% lower adjusted risk for all-cause mortality (P = 0.015) than the patients with type 2 diabetes, whereas risks for cardiac death and MACE did not differ significantly between the two groups. The adjusted risks for cardiac death, MACE, and all-cause mortality among patients with IGT and IFG did not significantly differ from those risks among patients with normal glycemic status. CONCLUSIONS Cardiac mortality or incidence of MACE in patients with CAD with prediabetes (i.e., IGT or IFG after revascularization, optimal medical therapy, or both) does not differ from those values in patients with normal glycemic status. |
| تدمد: | 1935-5548 0149-5992 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::2273117b8053ec885443174796678395Test https://doi.org/10.2337/dc18-2549Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........2273117b8053ec885443174796678395 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19355548 01495992 |
|---|